Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Onsolis (fentanyl buccal soluble film)
BEMA · 1 trial · 2 indications
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo |
| BEMA™ Fentanyl | EXPERIMENTAL | BioErodible MucoAdhesive (BEMA) Fentanyl |
| Name | Type | Description |
|---|---|---|
| BEMA™ | DRUG | BioDelivery Sciences International, Inc. (BDSI) has developed BioErodible MucoAdhesive (BEMA) Fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form. The BDSI product is a small soluble film that is placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the film readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of the film are water soluble, so the entire dosage form dissolves within 30 minutes of application. |
| Placebo | DRUG | - |
Inclusion Criteria: * Male or non-pregnant and non-lactating female. A female of child-bearing potential is eligible to participate in this study if she is using an acceptable method of birth control. * 18 years or older * Patient must have pain associated with cancer or cancer treatment. * Patient...
BEMA is an investigational small molecule developed for the treatment of breakthrough pain in cancer patients. It is being studied in adults aged 18 years and older. The Phase 3 program evaluated BEMA in subjects experiencing breakthrough pain related to cancer.
BEMA is being developed by Collegium Pharmaceutical, Inc., which trades under the ticker COLL. The company is responsible for the clinical development of BEMA for pain indications.
BEMA is in Phase 3 clinical development. One Phase 3 trial has been completed, and there are currently no active trials listed for BEMA. The completed trial was a randomized, double-blind, placebo-controlled study.
BEMA has been studied in one completed Phase 3 trial, NCT00293033, titled "Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects." The trial enrolled 152 participants in the United States and was randomized, double-blind, and placebo-controlled.
Yes, BEMA and BEMA™ refer to the same investigational drug candidate. BEMA™ is the trademarked name used by Collegium Pharmaceutical, Inc. for this product.